Flulaval & Fluarix Vaccines manufactured by GlaxoSmithKline using MMCAP Infuse Agreement (GSK…

The Virginia Department of Health awarded a contract to GlaxoSmithKline Holdings Inc. on August 31, 2026, for the provision of influenza vaccines under the Medicaid Managed Care Purchasing Alliance Program (MMCAP) Infuse Agreement. The contract encompasses the supply of Flulaval and Fluarix vaccines, which are manufactured by GlaxoSmithKline. The cumulative contract value is $400,000.00, with delivery specified to Pharmacy Services, Attn: Samantha James, located at 7870 Villa Park Drive, Suite 300, Henrico, Virginia 23228. The contract extends through December 31, 2026.

This procurement is executed under the existing GSK Influenza Contract No. MMS2200724 framework agreement, ensuring compliance with established Medicaid purchasing protocols and pricing structures. The vaccine delivery represents a critical component of Virginia's public health immunization initiatives, facilitating the distribution of seasonal influenza prophylaxis through the state's managed care system. The engagement with GlaxoSmithKline as the prime contractor ensures continuity of supply for this essential pharmaceutical intervention during the specified performance period.